Lakefront Biotherapeutics NV 6-K, filed Jun 25, 2025
Lakefront Biotherapeutics NV (LKFT)
About this 6-K
Lakefront Biotherapeutics NV filed this 6-K on June 25, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2025
Commission File Number: 001-37384
GALAPAGOS NV
(Translation of registrant's name
into English)
Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive
office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
[ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Henry Gosebruch and Aaron Cox, included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, and 333-283361).
On June 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
Exhibit 99.1. Press release dated June 23, 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GALAPAGOS NV | ||
| (Registrant) | ||
| Date: June 25, 2025 | /s/ Annelies Denecker | |
| Annelies Denecker | ||
| Company Secretary | ||
EXHIBIT 99.1
Galapagos Appoints Aaron Cox as Chief Financial Officer
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos
NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025.
Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth transition of responsibilities.
Aaron
brings more than two decades of leadership experience across biotechnology, capital markets, and M&A/corporate development. Most recently,
he served as Executive Vice President and Chief Financial Officer at Horizon Therapeutics plc, where he played a pivotal role in the company’s
$28 billion acquisition by Amgen. Prior to that, Aaron served as Horizon’s Head of Corporate Development and Chief of Staff to the
CEO, supporting capital markets strategy, M&A execution, and the company’s transformation into a fully integrated biotech. His
earlier career spans senior roles in investment banking.
“We are delighted to welcome Aaron to Galapagos,” said Henry Gosebruch, CEO of Galapagos. “Aaron will be a key partner in accelerating pipeline growth through business development and focusing our resources through disciplined financial management. His dealmaking background and experience managing a global financial organization will be invaluable as we continue transforming Galapagos with the goal of making a meaningful impact on the lives of patients worldwide.”
Aaron will lead the Finance, Accounting, Tax, Procurement, Communications and Investor Relations functions and will join the Executive Committee of Galapagos. As CFO, he will also work closely with leadership and the Board of Directors to execute transactions to build a new pipeline of innovative medicines and find a value-maximizing alternative for the cell therapy business.
“I am excited to join Galapagos at this pivotal moment,” said Aaron Cox, incoming CFO of Galapagos. “I look forward to working with Henry and the talented team to help shape the company’s next chapter, create value for our shareholders, and advance meaningful innovations for patients.”
Aaron holds a Bachelor’s degree in Finance from the University of Notre Dame and earned his MBA from the University of Chicago Booth School of Business.
In connection with this appointment, the Company will issue new restricted stock units (RSUs) and subscription rights.
About Galapagos
Galapagos is a biotechnology company with operations in Europe, the U.S., and
Asia, dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline
of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are
committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is to meet current
medical needs and to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For
additional information, please visit www.glpg.com or follow us on LinkedIn or X.
This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
For further information, please contact:
| Media inquiries: Marieke Vermeersch +32 479 490 603 media@glpg.com |
Investor inquiries: Glenn Schulman +1 412 522 6239 ir@glpg.com |
Forward-looking statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made
through the use of words or phrases such as “anticipate,” “expect,” “plan,” “estimate,”
“will,” “continue,” “aim,” “intend,” “future,” “potential,” “could,”
“indicate,” “forward,” as well as similar expressions. Forward-looking statements contained in this release include,
but are not limited to, statements regarding the announced leadership transition and changes in our Executive Committee and key personnel.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause Galapagos’ actual
results to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and
other factors include, without limitation, the possibility that Galapagos will encounter challenges retaining or attracting talent, that
our leadership transition may be disruptive to our business operations, risks related to our ability to effectively transfer knowledge
during this period of transition, as well as those risks and uncertainties identified in Galapagos’ Annual Report on Form 20-F for
the year ended 31 December 2024 filed with the U.S. Securities and Exchange Commission (SEC) and its subsequent filings with the SEC.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking
statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and
Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information
or subsequent events, circumstances, or changes in expectations, unless specifically required by law or regulation.